{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:01:50Z","timestamp":1791896510704,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T00:00:00Z","timestamp":1718496000000},"content-version":"vor","delay-in-days":381,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Chemical Biology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.chembiol.2023.05.007","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T20:01:17Z","timestamp":1686168077000},"page":"618-631.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation"],"prefix":"10.1016","volume":"30","author":[{"given":"Matthew L.","family":"Arwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon K.","family":"Harkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Weinstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen E.","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia D.","family":"Plana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Cirka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anniina T.","family":"Virtanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dikshat G.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Ceas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lawney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Yoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharine","family":"Leahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwan Geun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Silvennoinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevan R.","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinghu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5354-7403","authenticated-orcid":false,"given":"Nathanael S.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3018-597X","authenticated-orcid":false,"given":"Loretta S.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chembiol.2023.05.007_bib1","first-page":"119","article-title":"JAK-mutant myeloproliferative neoplasms","volume":"355","author":"Levine","year":"2012","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.chembiol.2023.05.007_bib2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.chembiol.2023.05.007_bib3","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2023.05.007_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2021.101331","article-title":"Has ph-like ALL superseded Ph+ ALL as the least favorable subtype?","volume":"34","author":"Tran","year":"2021","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.chembiol.2023.05.007_bib5","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ccr.2010.11.013","article-title":"Cooperative epigenetic modulation by cancer amplicon genes","volume":"18","author":"Rui","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.chembiol.2023.05.007_bib6","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1038\/s41467-018-04356-9","article-title":"Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models","volume":"9","author":"Ng","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2023.05.007_bib7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.12688\/f1000research.13167.1","article-title":"JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders","volume":"7","author":"Vainchenker","year":"2018","journal-title":"F1000Res."},{"key":"10.1016\/j.chembiol.2023.05.007_bib8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1084\/jem.20111694","article-title":"Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition","volume":"209","author":"Weigert","year":"2012","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.chembiol.2023.05.007_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2015.06.005","article-title":"Activity of the type II JAK2 inhibitor CHZ868 in B cell acute lymphoblastic leukemia","volume":"28","author":"Wu","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.chembiol.2023.05.007_bib10","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2023.05.007_bib11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.chembiol.2023.05.007_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40364-019-0166-y","article-title":"Targeted therapies for myeloproliferative neoplasms","volume":"7","author":"Li","year":"2019","journal-title":"Biomark. Res."},{"key":"10.1016\/j.chembiol.2023.05.007_bib13","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1182\/blood-2012-03-415448","article-title":"Targeting JAK1\/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia (ALL)","volume":"120","author":"Maude","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.chembiol.2023.05.007_bib14","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2011-12-389932","article-title":"Aberrant STAT5 and PI3K\/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia","volume":"120","author":"Tasian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.chembiol.2023.05.007_bib15","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1172\/JCI134424","article-title":"Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL","volume":"130","author":"Hurtz","year":"2020","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.chembiol.2023.05.007_bib16","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.278.5341.1309","article-title":"A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia","volume":"278","author":"Lacronique","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2023.05.007_bib17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1073\/pnas.0911726107","article-title":"Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia","volume":"107","author":"Yoda","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2023.05.007_bib18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/76923","article-title":"Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin","volume":"1","author":"Pandey","year":"2000","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.chembiol.2023.05.007_bib19","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.3389\/fimmu.2020.01557","article-title":"Modulation of signaling Mediated by TSLP and IL-7 in inflammation, autoimmune diseases, and cancer","volume":"11","author":"Markovi\u0107","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.chembiol.2023.05.007_bib20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1158\/2159-8290.CD-11-0324","article-title":"Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent","volume":"2","author":"Andraos","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.chembiol.2023.05.007_bib21","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jnci\/djr076","article-title":"Cancer burden in the HIV-infected population in the United States","volume":"103","author":"Shiels","year":"2011","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.chembiol.2023.05.007_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2015.06.006","article-title":"CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms","volume":"28","author":"Meyer","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.chembiol.2023.05.007_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049201","article-title":"Next-generation cDNA screening for oncogene and resistance phenotypes","volume":"7","author":"Shindoh","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.chembiol.2023.05.007_bib24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.chembiol.2023.05.007_bib25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1073\/pnas.0811223106","article-title":"A conserved protonation-dependent switch controls drug binding in the Abl kinase","volume":"106","author":"Shan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2023.05.007_bib26","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.chembiol.2011.04.011","article-title":"In situ kinase profiling reveals functionally relevant properties of native kinases","volume":"18","author":"Patricelli","year":"2011","journal-title":"Chem. Biol."},{"key":"10.1016\/j.chembiol.2023.05.007_bib27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fonc.2018.00287","article-title":"\"Do we know jack\" about JAK? A closer look at JAK\/STAT signaling pathway","volume":"8","author":"Bousoik","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.chembiol.2023.05.007_bib28","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1186\/s12885-017-3689-3","article-title":"GRcalculator: an online tool for calculating and mining dose-response data","volume":"17","author":"Clark","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.chembiol.2023.05.007_bib29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.3853","article-title":"Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs","volume":"13","author":"Hafner","year":"2016","journal-title":"Nat. Methods"},{"key":"10.1016\/j.chembiol.2023.05.007_bib30","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nbt.3882","article-title":"Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics","volume":"35","author":"Hafner","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.chembiol.2023.05.007_bib31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41698-021-00215-x","article-title":"Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia","volume":"5","author":"Downes","year":"2021","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.chembiol.2023.05.007_bib32","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1021\/acs.jmedchem.0c01952","article-title":"Structural insights into JAK2 inhibition by ruxolitinib, fedratinib, and derivatives thereof","volume":"64","author":"Davis","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.chembiol.2023.05.007_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106225","article-title":"c-Src binds to the cancer drug Ruxolitinib with an active conformation","volume":"9","author":"Duan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.chembiol.2023.05.007_bib34","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1158\/1535-7163.MCT-10-0053","article-title":"Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805","volume":"9","author":"Baffert","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.chembiol.2023.05.007_bib35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.chembiol.2023.05.007_bib36","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia","volume":"41","author":"Mullighan","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.chembiol.2023.05.007_bib37","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1182\/blood-2012-03-415448","article-title":"Targeting JAK1\/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"120","author":"Maude","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.chembiol.2023.05.007_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.942053","article-title":"JAK2 alterations in acute lymphoblastic leukemia: molecular insights for superior precision medicine strategies","volume":"10","author":"Downes","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.chembiol.2023.05.007_bib39","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.hoc.2017.04.003","article-title":"Mechanisms of resistance to JAK2 inhibitors in myeloproliferative neoplasms","volume":"31","author":"Meyer","year":"2017","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/j.chembiol.2023.05.007_bib40","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1101\/gad.307504.117","article-title":"JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias","volume":"32","author":"Kim","year":"2018","journal-title":"Genes Dev."},{"key":"10.1016\/j.chembiol.2023.05.007_bib41","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1084\/jem.20131371","article-title":"Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F","volume":"211","author":"Lundberg","year":"2014","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.chembiol.2023.05.007_bib42","article-title":"Jak2 V617F reversible activation shows an essential requirement for Jak2 V617F in myeloproliferative neoplasms","author":"Dunbar","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.chembiol.2023.05.007_bib43","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.chembiol.2023.05.007_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115326","article-title":"Hi-JAK-ing the ubiquitin system: the design and physicochemical optimisation of JAK PROTACs","volume":"28","author":"Shah","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.chembiol.2023.05.007_bib45","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1182\/blood.2020006846","article-title":"Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia","volume":"138","author":"Chang","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.chembiol.2023.05.007_bib46","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acsmedchemlett.9b00597","article-title":"PROTAC Technology: opportunities and challenges","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.chembiol.2023.05.007_bib47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.chembiol.2023.05.007_bib48","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jaci.2018.07.022","article-title":"Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations","volume":"143","author":"Hammaren","year":"2019","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.chembiol.2023.05.007_bib49","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3389\/fonc.2018.00560","article-title":"Hyperactivation of oncogenic JAK3 mutants depend on ATP binding to the pseudokinase domain","volume":"8","author":"Raivola","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.chembiol.2023.05.007_bib50","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","article-title":"Processing of X-ray diffraction data collected in oscillation mode","volume":"276","author":"Otwinowski","year":"1997","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.chembiol.2023.05.007_bib51","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1107\/S2059798319011471","article-title":"Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix","volume":"75","author":"Liebschner","year":"2019","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"10.1016\/j.chembiol.2023.05.007_bib52","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr. D Biol. Crystallogr."}],"container-title":["Cell Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945623001502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945623001502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T17:53:34Z","timestamp":1726682014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451945623001502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2451945623001502"],"URL":"https:\/\/doi.org\/10.1016\/j.chembiol.2023.05.007","relation":{},"ISSN":["2451-9456"],"issn-type":[{"value":"2451-9456","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation","name":"articletitle","label":"Article Title"},{"value":"Cell Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chembiol.2023.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}